

## ORAL MANIFESTATIONS OF NEUROLOGICAL DISORDERS - A REVIEW

*Dr. Aruna Sivados*

*Senior Resident- Annai medical college and hospital (Rajalakshmi Health City), Pennalur, Sriperumbudur, Chennai*

### **ABSTRACT**

About 30-40% sensory and motor nerves of the body reside in oral and maxillofacial region. Dental professionals form an indomitable team for the early diagnosis of some neurological diseases. The dental treatment of patients with neurological disorders comprises of identification and diagnosis of the disease, risk factors followed by appropriate treatment and maintenance of oral hygiene.

**KEYWORDS:** Oral, Pathology, Maxillofacial, Neuro, Dental

---

### **Article History**

**Received: 22 Jun 2024 | Revised: 24 Jun 2024 | Accepted: 30 Jun 2024**

---

### **INTRODUCTION**

Oral and maxillofacial region houses 30% to 40% of neural networks in relation to sensory and motor origin<sup>1,2</sup>. Oral manifestations of neurological diseases are of utmost importance pertaining to Parkinson's disease, neoplasms affecting orofacial neurological apparatus and Sturge Weber syndrome<sup>1</sup>. In this scientific article, we have discussed the most common neurological disorders with pathognomonic oral and maxillofacial manifestations followed by their dental management.

### **NEURAL DISORDERS**

Parkinson's disorder – It is a degenerative disorder resulting in the loss of striatal dopaminergic neurons leading to bradykinesia, tremor and cogwheel rigidity. In nondopaminergic areas, symptoms of non-motor origin such as depression, sleep disorder and cognitive changes occur<sup>4</sup>. Trauma, dairy products, environment, pesticides and melanotic conditions are major risk factors<sup>5</sup>. Clinical features include apathy, sensory dysfunction, mood disorder, fatigue, dysautonomia, postural instability and insomnia. Oral features include jaw tremors, dysgeusia, tongue rigidity, xerostomia, orofacial pain, dental caries, periodontitis and incompetent lips<sup>8,9,10,11</sup>. Management component includes toothbrushes with a wider grip, supine position, high-speed suction apparatus, sugar-free chewing gum, pit-fissure sealants, mouth guard and salivary substitutes.

Bell's palsy – It is a neurological disorder involving lower motor neurons resulting in weakness of facial muscles. Risk factors include cold, inflammation, anatomy, viral and ischaemia<sup>16,17,18</sup>. Obesity, diabetes, pregnancy, upper respiratory tract infection, preeclampsia and hypertension are risk factors<sup>19,20</sup>. Clinical appearance includes paralysis and weakness of orofacial musculature in relation to lower motor neurons involving one side leading to hyperacusis, inability to wink an eye, inability to smile, inability to raise eyebrows and pain pertaining to the mastoid region or auditory region. Dysgeusia, hypersalivation, decreased lacrimal secretions and functional demand of mastication forms the oral component<sup>15,19,21,22</sup>.

Oral management comprises of mouthwashes, fluoride application, artificial saliva, wedge resection and botulinum toxin injection.

Multiple sclerosis – This demyelinating disease is of inflammatory and autoimmune origin. Risk factors include trauma, environment, genetics and viral. Clinical features include dysarthria, vertigo, nystagmus, loss of facial senses, diplopia and ophthalmoplegia. Poor oral hygiene, trigeminal neuralgia, facial palsy, and paresthesia of the lower lip and chin form the oral counterpart. Dental management includes chlorhexidene mouthwashes, fluorides, salivary substitutes and varnishes.

Sturge-Weber syndrome – Also known as encephalotrigeminal angiomas which occurs due to angiogenic factors. Vascular malformation of the brain, glaucoma, intracranial leptomenigeal. angioma, post-wine birthmark and angiomas of maxillary and ophthalmic branches of the trigeminal nerve are seen clinically. Vascular malformations in relation to maxillary gingiva, mandibular gingiva, labial mucosa, palatal mucosa and tongue region. Haemostatic measures are to be followed in order to avoid haemorrhagic tendencies.

Pringle Bourneville phacomatosis – Commonly known as tuberous sclerosis complex involving the nervous system, skin, kidney, heart and lungs. Hamartin and tuberin are proteins which code for TSC1 and TSC2 genes. Lymphangiomyomatosis, cardiac rhabdomyoma, subependymal giant cell astrocytoma, renal angiomyolipoma and facial angiofibromas form the major criteria. Retinal achromatic patch, bone cysts cerebral white matter radial migration lines and multiple renal cysts form the minor criteria. Oral counterpart includes high arched palate, delayed tooth eruption, haemangiomas, cleft lip and cleft palate. Dental management is planned by tooth restoration, cleft lip–cleft palate surgical repair and correction of gingival irregularities.

Von Recklinghausen's disease – This type of neurofibromatosis is due to defective gene NF1 located at the 17q11.2 chromosome. Clinical features include scoliosis, neurofibromas, optic gliomas and cafe-au-lait spots. The oral component includes malocclusion, pain, impacted tooth, missing tooth, maxillary hyperplasia and gingival irregularities. Conservative or surgical management in conjunction with biopsy. A biopsy must be done. Conservative or surgical management can be done.

## CONCLUSIONS

Management of oral and maxillofacial diseases and disorders needs to be attended in an emergency basis due to the involvement of neurological apparatus. Early diagnosis and detection of neurological diseases and disorders lead to better maintenance of oral hygiene.

## REFERENCES

1. Wahi S, Singh S, Wahi S, Kumar P. Oral manifestations of neurological disorders: A key note. *Niger J Basic Clin Sci* 2013;10:38-40.
2. M. Hashem, S. Vellappally, H. Fouad, M. Luqman and A. E. Youssef, "Predicting Neurological Disorders Linked to Oral Cavity Manifestations Using an IoMT-Based Optimized Neural Networks," in *IEEE Access*.2020; pp. 190722-190733.
3. Kalia LV, Lang AE. "Parkinson's disease". *Lancet*.2015; 386 (9996): 896–912.

4. DeMaagd G, Philip A. *Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis*. P T. 2015;40(8):504-532.
5. Ascherio A, Schwarzschild MA. *The epidemiology of Parkinson's disease: risk factors and prevention*. *Lancet Neurol*. 2016 Nov;15(12):1257-1272.
6. Jankovic *Parkinson's disease: clinical features and diagnosis*. *Journal of Neurology, Neurosurgery & Psychiatry* 2008;79:368376.
7. Massano J, Bhatia KP. *Clinical approach to Parkinson's disease: features, diagnosis, and principles of management*. *Cold Spring Harb Perspect Med*. 2012;2(6):a008870.
8. Zlotnik Y, Balash Y, Korczyn AD, Giladi N, Gurevich T. *Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes*. *Parkinsons Dis*. 2015;2015:379482.
9. M. Bakke, S. L. Larsen, C. Laurrup, and M. Karlsborg, "Orofacial function and oral health in patients with Parkinson's disease," *European Journal of Oral Sciences*, vol. 119, no. 1, pp. 27–32, 2011.
10. Newadkar UR, Khairnar SJ, Dodamani AS, Newadkar RD. *Oral Health Issues and Challenges in Parkinson's Disease*. *Int J Nutr Pharmacol Neurol Dis* 2017;7:54-9.
11. Kieser J, Jones G, Borlase G. *Dental treatment of patients with neurodegenerative disease*. *N Z Dent J* 1999;95:130-4.
12. Grover, Satbir & Rhodus, Nelson. *Dental management of Parkinson's disease*. *Northwest Dentistry*. 2011. 90. 13-9.
13. South AR, Somers SM, Jog MS. *Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study*. *Neurology* 2010;74:1198-202.
14. De Bowes SL, Tolle SL, Bruhn AM. *Parkinson's disease: considerations for dental hygienists*. *Int J Dent Hyg* 2013;11:15-21.
15. Khator, Apurva & Motwani, Mukta. *Neuromuscular disorders affecting the Oral and Maxillofacial region and their Dental management*. *International Journal of Dentistry Research*. 2019;4:13-19.
16. Somasundara D, Sullivan F. *Management of Bell's palsy*. *Aust Prescr*. 2017;40(3):94-97.
17. De Diego-Sastre JI, Prim-Espada MP, Fernández-García F. *The epidemiology of Bell's palsy*. *Rev Neurol* 2005;41:287-90.
18. Zhang W, Xu L, Luo T, Wu F, Zhao B, Li X. *The etiology of Bell's palsy: a review*. *J Neurol*. 2020;267(7):1896-1905.
19. Neville, B.W., Damm, D.D., Allen, C.M. and Chi, A.C. *Oral & Maxillofacial Pathology*. 4th Edition, WB Saunders, Elsevier. 2016.
20. Zhang, W., Xu, L., Luo, T. et al. *The etiology of Bell's palsy: a review*. *J Neurol*. 2020; 267, 1896–1905.
21. Eviston TJ, Croxson GR, Kennedy PGE, et al. *Bell's palsy: aetiology, clinical features and multidisciplinary care* *journal of Neurology, Neurosurgery & Psychiatry* 2015;86:1356-1361.

22. Mumenthaler M, Mattle H. *Fundamentals of Neurology*. Germany: Thieme.2006; pp. 197.
23. Klobucar, Robert & Kingsmill, Virginia & Venables, Vanessa & Bisase, Brian & Nduka, Charles. *A dental perspective of facial palsy*. *Faculty Dental Journal*. 2012;3: 202-207.
24. Goldenberg MM. *Multiple sclerosis review*. *P T*. 2012;37(3):175-184.
25. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. *Multiple sclerosis: risk factors, prodromes, and potential causal pathways*. *Lancet Neurol*. 2010 Jul;9(7):727-39.
26. Ford H. *Clinical presentation and diagnosis of multiple sclerosis*. *Clin Med (Lond)*. 2020;20(4):380-383.
27. Chemały D, Lefrançois A, Pérusse R. *Oral and maxillofacial manifestations of multiple sclerosis*. *J Can Dent Assoc*. 2000
28. *Dec*;66(11):600-5.
29. Zhang GQ, Meng Y. *Oral and craniofacial manifestations of multiple sclerosis: implications for the oral health care provider*. *Eur Rev Med Pharmacol Sci*. 2015 Dec;19(23):4610-20.
30. G.A. Scardina, F. Carini, G. Fuca, V. Valenza and P. Messina, 2007. *Multiple Sclerosis: Oral Manifestations and Dental Implications*. *Research Journal of Biological Sciences*, 2: 444-448
31. Fischer, D. J., Epstein, J. B., & Klasser, *Multiple sclerosis: an update for oral health care providers*. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2009;108(3), 318–327.
32. Maslin, Jessica S, Dorairaj, Syril K, Ritch, Robert *Sturge-Weber Syndrome*. *Encephalotrigeminal Angiomatosis*. *Asia-Pacific Journal of Ophthalmology: November/December 2014 - Volume 3 - Issue 6 - p 361-367*.
33. Neerupakam M, Reddy PS, Babu BA, Krishna GV. *Sturge Weber Syndrome: A Case Study*. *J Clin Diagn Res*. 2017;11(5):ZD12-ZD14.
34. Aydin A, Cakmakçi H, Kovanlikaya A, Dirik E. *Sturge-Weber syndrome without facial nervus*. *Pediatr. Neurol*. 2000, 22:400402.
35. Zabel, T & Reesman, Jennifer & Wodka, Ericka & Gray, Robert & Suskauer, Stacy & Turin, Elizabeth & Ferenc, Lisa & Lin, Doris & Kossoff, Eric & Comi, Anne. *Neuropsychological Features and Risk Factors in Children With Sturge-Weber Syndrome: Four Case Reports*. *The Clinical neuropsychologist*. 2010.24. 841-59.
36. Neto FXP, Junior MAV, Ximenes LS, Jacob CCS, Junior AGR, Palheta CP, et al. *Clinical Features of Sturge-Weber Syndrome*. *Int. Arch. Otorhinolaryngol*. 2008;12(4):565-570.
37. Tripathi AK, Kumar V, Dwivedi R, et al *Sturge-Weber syndrome: oral and extra-oral manifestations*. *Case Reports* 2015;2015:bcr2014207663.
38. Royle HE, Lapp R, Ferrara ED. *The Sturge-Weber syndrome*. *Oral Surg Oral Med Oral Pathol* 1966;22:490–7.
39. Kaur M. *Orofacial manifestation of Sturge-Weber syndrome: A case report with review*. *J Orofac Sci* 2012;4:70-4.

40. Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado MCDM. Tuberous sclerosis complex: review based on new diagnostic criteria. *An Bras Dermatol.* 2018;93(3):323-331.
41. Rendtorff ND, Bjerregaard B, Frödin M, Kjaergaard S, Hove H, Skovby F, Brøndum-Nielsen K, Schwartz M."Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations". *Human Mutation.*2005; 26 (4): 374–83.
42. Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. *Pediatrics.* 2011 Jan;127(1):e117–25.
43. Tonekaboni SH, Tonekaboni SH, Tousi P, et al. Clinical and Para clinical Manifestations of Tuberous Sclerosis: A Cross Sectional Study on 81 Pediatric Patients. *Iran J Child Neurol.* 2012;6(3):25-31.
44. Scully C. Orofacial manifestations in tuberous sclerosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1977;44:706–16.
45. Sodhi S, Dang RS, Brar G. Tuberous sclerosis with oral manifestations: A rare case report. *Int J Appl Basic Med Res.* 2016;6(1):60-62.
46. Reddy LS, Singh T, Reddy VK, Mittal S. Oral lesions in tuberous sclerosis. *J Indian Acad Oral Med Radiol* 2018;30:189-92.
47. Goyal L, Agarwal P, Reddy GS, Jain K. Diagnosis and treatment considerations of atypical oral pain in tuberous sclerosis. *J Family Med Prim Care* 2020;9:2121-4.
48. Hillier JC, Moskovic E. The soft tissue manifestations of neurofibromatosis type I. *Clin Radiol.* 2005;60:960–7.
49. Ghalayani P, Saberi Z, Sardari F. Neurofibromatosis type I (von Recklinghausen's disease): A family case report and literature review. *Dent Res J (Isfahan).* 2012;9(4):483-488.
50. Friedman JM, Gutmann DH, MacCollin M, Riccardi Y. Phenotype, natural history and pathogenesis. Baltimore: The Johns Hopkins University Press. *Neurofibromatosis.*1999.
51. Santos MS, Campos WG, Esteves CV, Zambon CE, Rocha AC, Machado GG. Von Recklinghausen disease/type I neurofibromatosis and its association with orofacial changes: Literature review and case report. *J. Oral Diag.* 2019;4(1).
52. Shetty B, Umesh Y, Kranti K, Seshan H. Periodontal manifestations of von Recklinghausen neuro fibromatosis. *J Indian Soc Periodontol.* 2013;17(2):253-256.
53. Romero-Reyes M, Salvemini D. Cancer and orofacial pain. *Med Oral Patol Oral Cir Bucal.* 2016;21(6):e665-e671.
54. Capodiferro, S.; Limongelli,L.; Favia, G. Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview. *Medicina* 2021, 57, 271.
55. Aljammali, Zainab Mahmood. "Effect Of Drugs On Teeth And Gums-A Review." *TJPRC: International Journal of Pedodontics and Preventive Dentistry (TJPRC: IJPPD) Vol 1: 1-8.*

56. Senthilnathan, C. V., A. Gurulakshmi, and K. G. Mohan. "Effects of isometric neck exercises in improving cervical range of motion in long time helmet wearers." *TJPRC: International Journal of Physiotherapy & Occupational Therapy (TJPRC: IJPOT)* 1 (2015): 9-16.
57. Aljammali, Zainab Mahmood. "Effect Of Drugs On Teeth And Gums-A Review." *TJPRC: International Journal of Pedodontics and Preventive Dentistry (TJPRC: IJPPD)* Vol 1: 1-8.

